Vinia is not FDA approved. It is classified as a dietary supplement, which means the FDA does not evaluate it for safety or effectiveness before it goes on sale. This is a common point of confusion: in the United States, only drugs, medical devices, and certain food additives go through a formal FDA approval process. Supplements like Vinia follow a completely different regulatory path.
How Vinia Is Regulated
Vinia, made by BioHarvest Sciences, is a red grape powder sold as a dietary supplement. Under federal law, dietary supplements do not need FDA approval before reaching consumers. Instead, the manufacturer is responsible for ensuring the product is safe and that any claims on the label are truthful and not misleading.
What BioHarvest has done is file Structure/Function Claims (SFC) notifications with the FDA. These are formal notices telling the agency what health-related statements the company plans to put on its packaging. BioHarvest has submitted claims including that Vinia “prevents lipid oxidation,” “protects your body by preventing oxidative damage to your cells,” and “reduces oxidation of LDL cholesterol.” The company also describes Vinia as a “full spectrum blood flow superfood from red grapes that works at the cellular level.”
Filing these notifications is a legal requirement, but it is not the same as receiving FDA approval. The FDA does not review the evidence behind the claims or confirm they are accurate. Products sold under structure/function claims are required to carry a disclaimer stating that the FDA has not evaluated the claim and that the product is not intended to diagnose, treat, cure, or prevent any disease.
What Vinia Claims to Do
BioHarvest markets Vinia primarily around cardiovascular and circulatory benefits. The company states that Vinia supports blood flow through vascular dilation, which in turn helps deliver oxygen and nutrients to muscles during physical activity. In its FDA filings, BioHarvest references in-vitro (lab-based, not human) studies showing that Vinia decreases a protein called endothelin-1, which constricts blood vessels, and increases nitric oxide, which relaxes them.
These are plausible mechanisms. Nitric oxide is well established as a key player in blood vessel relaxation and healthy circulation. However, showing that something works in a lab dish is a much lower bar than proving it works in the human body at the doses found in a supplement capsule. The distinction matters because in-vitro results frequently do not translate to real-world benefits.
What the Clinical Evidence Shows
One randomized, double-blinded clinical trial published in Frontiers in Pharmacology tested a grape extract (Vitis vinifera) on cognitive function in healthy older adults. During that study, no adverse effects were detected, and the extract was described as “well-tolerated.” That is a useful safety signal, but a single trial in healthy volunteers is a limited evidence base.
Vinia contains piceid, a naturally occurring form of resveratrol found in grapes. BioHarvest has promoted this as a more effective delivery form of resveratrol. The reality is more nuanced. Research published in PLOS One compared piceid and resveratrol directly and found that cells actually absorbed free resveratrol much faster and in greater quantities than piceid. In liver cells, resveratrol reached its peak intracellular level within 30 minutes, while piceid levels were still slowly climbing at the three-hour mark. Piceid was harder for cells to take up overall. This does not necessarily mean Vinia is ineffective, but it does complicate the marketing narrative that piceid is a superior form of resveratrol.
What “Not FDA Approved” Actually Means for You
The lack of FDA approval does not automatically mean a supplement is dangerous or useless. It means no independent government body has verified the manufacturer’s claims. You are relying on the company’s own quality control, its own interpretation of its own studies, and its honesty in labeling.
For context, the entire U.S. supplement industry operates this way. Vitamins, fish oil, probiotics, and protein powders all sit in the same regulatory category as Vinia. The FDA can step in after the fact if a product is found to be unsafe or if its marketing crosses the line into drug-like claims (such as saying a supplement treats or cures a disease), but the agency does not act as a gatekeeper before the product hits shelves.
If you are considering Vinia specifically for heart health or circulation, it is worth knowing that the strongest claims in its marketing rely on lab studies rather than large human trials. The safety profile looks clean based on available data, but the efficacy question remains open. No supplement can legally claim to treat cardiovascular disease, and Vinia’s own filings are carefully worded to stay within the structure/function boundary: supporting blood flow, reducing oxidation, promoting circulation. These are softer claims than “lowers blood pressure” or “prevents heart attacks,” and that distinction is intentional.